Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Amgen (AMGN) is a heavily searched stock, despite its shares returning -3.2% over the past month, underperforming the S&P 500. The biotech firm recently reported strong quarterly results, beating EPS estimates by 17.79% and revenue by 2.47%, and has consistently surpassed consensus expectations. Analysts project modest earnings and revenue growth for the current and next fiscal years, leading to a Zacks Rank #3 (Hold) rating, suggesting an in-line market performance. Additionally, Amgen's valuation indicates it is trading at a discount to its peers, earning a Zacks Value Style Score of 'B'.

Analysis

Amgen (AMGN) presents a mixed profile, characterized by strong recent operational performance but a decelerating growth outlook that is weighing on its stock. The company's shares have underperformed, declining 3.2% over the past month against the S&P 500's 5.2% gain, despite a robust history of earnings execution. In its last reported quarter, Amgen posted a 9.4% year-over-year revenue increase and an EPS surprise of 17.79%, having beaten EPS estimates for four consecutive quarters. However, forward-looking consensus estimates justify the market's tepid sentiment. While the current fiscal year's earnings are projected to grow 4.9%, this is expected to slow to 2.2% in the next fiscal year. Similarly, revenue growth is forecast to decelerate from 5.4% this year to just 1.6% next year. This outlook, coupled with largely unchanged analyst estimates over the past 30 days, supports the stock's Zacks Rank #3 (Hold) rating. On valuation, Amgen scores a 'B' for value, indicating it is trading at a discount to its peers, suggesting the market has already priced in the anticipated slowdown.

Key Decisions for Investors

• Given the stock's discounted valuation relative to peers and a strong history of beating earnings, value-oriented investors may consider the current price an entry point, but must accept a muted growth profile.
• Investors should exercise caution regarding near-term price appreciation, as the stock's recent underperformance and significant forecast deceleration in both revenue and earnings growth support the 'Hold' rating.
• Monitor future analyst earnings revisions closely, as the current stagnation in estimates is a key headwind; any significant positive revision could serve as a primary catalyst for a change in the stock's trajectory.